WHO identifies achieving Universal Health Coverage (UHC) as a strategic priority, which encompasses a full range of essential health services, of which technology constitutes a core component. It is a significant challenge for many countries, especially low- and middle- income countries (LMICs), to increase their use of scarce public resources to ensure their citizens’ access to innovative pharmaceuticals. Such a dilemma of high costs, limited access, and UHC is calling for innovative approaches and solutions.
This webinar will map the market entry, reimbursement policy for innovative drugs and HTA roles, value frameworks and methodology and institutional challenges and potential regional/international HTA collaboration.